Research has established that birch bark triterpenes (TE) have notable wound healing properties. On a cellular level, TE enhances re-epithelialization and reformation of the epithelial barrier. Other research has shown improved epidermal tissue reconstitution, significantly enhancing cell proliferation in the basal layer and promoting the development of a well-formed stratum corneum. A recent research partnership has allowed us to create a novel, nano technology delivery system to deliver these triterpenes subdermally to improve efficacy. This technology was successfully demonstrated by Dr Eric Morrison in a Phase 1 NSF grant which showed the ability of this system to deliver ibuprofen subdermally through topical application. This delivery system can also be applied to other natural products and anti oxidant vitamins for wound and skin care applications
Primary Application Area: Biotech, Pharma
Technology Development Status: Proven Manufacturability
Technology Readiness Level: TRL 5
Vetted Programs/Awards: Betula Extractives received an STTR NSF Phase 1 grant entitled “Semisynthetic Manufacturing of Core Natural Triterpenoids from Outer Birch Bark Extract” and received a Defense Innovation Award at Tampa TechConnect event in October 2018. Dr. Eric Morrison received an NSF SBIR Phase I:"Lipoleosomes as Carriers for Topical Ibuprofen".
Organization Type: Early-stage Startup (Seed)
Showcase Booth #: 19M
GOVT/EXTERNAL FUNDING SOURCES
External Funding to Date: We have received $600,000 of funding in the form of angel investment and economic development loans and grants.